Cargando…

Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti-Toxoplasma Immunity

Innate immunity acts as the first line of defense against pathogen invasion. During Toxoplasma gondii infection, multiple innate immune sensors are activated by invading microbes or pathogen-associated molecular patterns (PAMPs). However, how inflammasome is activated and its regulatory mechanisms d...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Zhiqiang, Wu, Dan, Lu, Jiansen, Zhang, Yufen, Yu, Shao-Meng, Xie, Yingchao, Li, Hongyu, Yang, Jianwu, Lai, De-Hua, Zeng, Ke, Jiang, Huaji, Lun, Zhao-Rong, Yu, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765454/
https://www.ncbi.nlm.nih.gov/pubmed/36214572
http://dx.doi.org/10.1128/mbio.02361-22
_version_ 1784853490510594048
author Hu, Zhiqiang
Wu, Dan
Lu, Jiansen
Zhang, Yufen
Yu, Shao-Meng
Xie, Yingchao
Li, Hongyu
Yang, Jianwu
Lai, De-Hua
Zeng, Ke
Jiang, Huaji
Lun, Zhao-Rong
Yu, Xiao
author_facet Hu, Zhiqiang
Wu, Dan
Lu, Jiansen
Zhang, Yufen
Yu, Shao-Meng
Xie, Yingchao
Li, Hongyu
Yang, Jianwu
Lai, De-Hua
Zeng, Ke
Jiang, Huaji
Lun, Zhao-Rong
Yu, Xiao
author_sort Hu, Zhiqiang
collection PubMed
description Innate immunity acts as the first line of defense against pathogen invasion. During Toxoplasma gondii infection, multiple innate immune sensors are activated by invading microbes or pathogen-associated molecular patterns (PAMPs). However, how inflammasome is activated and its regulatory mechanisms during T. gondii infection remain elusive. Here, we showed that the infection of PRU, a lethal type II T. gondii strain, activates inflammasome at the early stage of infection. PRU tachyzoites, RNA and soluble tachyzoite antigen (STAg) mainly triggered the NLRP3 inflammasome, while PRU genomic DNA (gDNA) specially activated the AIM2 inflammasome. Furthermore, mice deficient in AIM2, NLRP3, or caspase-1/11 were more susceptible to T. gondii PRU infection, and the ablation of inflammasome signaling impaired antitoxoplasmosis immune responses by enhancing type I interferon (IFN-I) production. Blockage of IFN-I receptor fulfilled inflammasome-deficient mice competent immune responses as WT mice. Moreover, we have identified that the suppressor of cytokine signaling 1 (SOCS1) is a key negative regulator induced by inflammasome-activated IL-1β signaling and inhibits IFN-I production by targeting interferon regulatory factor 3 (IRF3). In general, our study defines a novel protective role of inflammasome activation during toxoplasmosis and identifies a critical regulatory mechanism of the cross talk between inflammasome and IFN-I signaling for understanding infectious diseases.
format Online
Article
Text
id pubmed-9765454
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-97654542022-12-21 Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti-Toxoplasma Immunity Hu, Zhiqiang Wu, Dan Lu, Jiansen Zhang, Yufen Yu, Shao-Meng Xie, Yingchao Li, Hongyu Yang, Jianwu Lai, De-Hua Zeng, Ke Jiang, Huaji Lun, Zhao-Rong Yu, Xiao mBio Research Article Innate immunity acts as the first line of defense against pathogen invasion. During Toxoplasma gondii infection, multiple innate immune sensors are activated by invading microbes or pathogen-associated molecular patterns (PAMPs). However, how inflammasome is activated and its regulatory mechanisms during T. gondii infection remain elusive. Here, we showed that the infection of PRU, a lethal type II T. gondii strain, activates inflammasome at the early stage of infection. PRU tachyzoites, RNA and soluble tachyzoite antigen (STAg) mainly triggered the NLRP3 inflammasome, while PRU genomic DNA (gDNA) specially activated the AIM2 inflammasome. Furthermore, mice deficient in AIM2, NLRP3, or caspase-1/11 were more susceptible to T. gondii PRU infection, and the ablation of inflammasome signaling impaired antitoxoplasmosis immune responses by enhancing type I interferon (IFN-I) production. Blockage of IFN-I receptor fulfilled inflammasome-deficient mice competent immune responses as WT mice. Moreover, we have identified that the suppressor of cytokine signaling 1 (SOCS1) is a key negative regulator induced by inflammasome-activated IL-1β signaling and inhibits IFN-I production by targeting interferon regulatory factor 3 (IRF3). In general, our study defines a novel protective role of inflammasome activation during toxoplasmosis and identifies a critical regulatory mechanism of the cross talk between inflammasome and IFN-I signaling for understanding infectious diseases. American Society for Microbiology 2022-10-10 /pmc/articles/PMC9765454/ /pubmed/36214572 http://dx.doi.org/10.1128/mbio.02361-22 Text en Copyright © 2022 Hu et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Hu, Zhiqiang
Wu, Dan
Lu, Jiansen
Zhang, Yufen
Yu, Shao-Meng
Xie, Yingchao
Li, Hongyu
Yang, Jianwu
Lai, De-Hua
Zeng, Ke
Jiang, Huaji
Lun, Zhao-Rong
Yu, Xiao
Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti-Toxoplasma Immunity
title Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti-Toxoplasma Immunity
title_full Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti-Toxoplasma Immunity
title_fullStr Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti-Toxoplasma Immunity
title_full_unstemmed Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti-Toxoplasma Immunity
title_short Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti-Toxoplasma Immunity
title_sort inflammasome activation dampens type i ifn signaling to strengthen anti-toxoplasma immunity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765454/
https://www.ncbi.nlm.nih.gov/pubmed/36214572
http://dx.doi.org/10.1128/mbio.02361-22
work_keys_str_mv AT huzhiqiang inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity
AT wudan inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity
AT lujiansen inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity
AT zhangyufen inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity
AT yushaomeng inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity
AT xieyingchao inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity
AT lihongyu inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity
AT yangjianwu inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity
AT laidehua inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity
AT zengke inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity
AT jianghuaji inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity
AT lunzhaorong inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity
AT yuxiao inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity